Literature DB >> 25035232

Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.

Lichun Ma1, Debby D Wang2, Yiqing Huang3, Maria P Wong4, Victor H F Lee4, Hong Yan2.   

Abstract

Epidermal growth factor receptor (EGFR) mutation-induced drug resistance leads to a limited efficacy of tyrosine kinase inhibitors during lung cancer treatments. In this study, we explore the correlations between the local surface geometric properties of EGFR mutants and the progression-free survival (PFS). The geometric properties include local surface changes (four types) of the EGFR mutants compared with the wild-type EGFR, and the convex degrees of these local surfaces. Our analysis results show that the Spearman׳s rank correlation coefficients between the PFS and three types of local surface properties are all greater than 0.6 with small P-values, implying a high significance. Moreover, the number of atoms with solid angles in the ranges of [0.71, 1], [0.61, 1] or [0.5, 1], indicating the convex degree of a local EGFR surface, also shows a strong correlation with the PFS. Overall, these characteristics can be efficiently applied to the prediction of drug resistance in lung cancer treatments, and easily extended to other cancer treatments.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alpha shape; Drug resistance; EGFR mutation; Lung cancer; Protein surface geometric properties; Solid angle

Mesh:

Substances:

Year:  2014        PMID: 25035232     DOI: 10.1016/j.compbiomed.2014.06.016

Source DB:  PubMed          Journal:  Comput Biol Med        ISSN: 0010-4825            Impact factor:   4.589


  4 in total

1.  EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.

Authors:  Lichun Ma; Debby D Wang; Yiqing Huang; Hong Yan; Maria P Wong; Victor H F Lee
Journal:  BMC Bioinformatics       Date:  2015-03-14       Impact factor: 3.169

2.  Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.

Authors:  Bin Zou; Victor H F Lee; Hong Yan
Journal:  BMC Bioinformatics       Date:  2018-03-07       Impact factor: 3.169

3.  Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations.

Authors:  Mengxu Zhu; Debby D Wang; Hong Yan
Journal:  BMC Mol Cell Biol       Date:  2021-06-10

4.  Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics.

Authors:  Lichun Ma; Bin Zou; Hong Yan
Journal:  Proteome Sci       Date:  2016-09-08       Impact factor: 2.480

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.